glenmark
A new way for a new world

August 23, 2019

To,
Mr. Amit Kursija
Surveillance Department,
The National Stock Exchange of India Ltd.,
Plot No. C/1, G Block,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051.

Scrip Name: GLENMARK

Ref: Your email dated August 23, 2019

Dear Sir,

Sub: Clarification on media report titled as 'Glenmark in talks to sell up to 30% in API biz to PremjiInvest' published on economictimes.indiatimes.com dated 23rd August, 2019

We refer to your e-mail dated August 23, 2019 seeking clarification on media report titled as 'Glenmark in talks to sell up to 30% in API biz to PremjiInvest' published on economictimes.indiatimes.com

The news pertaining to the investors in the above mentioned media report is speculative in nature.

The Company is not aware of the source which resulted in the above mentioned news item and as a matter of policy, the Company would not like to comment on such speculation.

We have been proactive in informing the Exchange about the events of the Company and we will continue to do so.

Request you to kindly take the same on record.

Thanking you,

Yours faithfully,
For Glenmark Pharmaceuticals Limited

Harish Kuber
Company Secretary & Compliance Officer

Glenmark Pharmaceuticals Ltd.
Glenmark House, B D Sawant Marg, Andheri (E), Mumbai - 400 099, India
T: 91 22 4018 9999 F: 91 22 4018 9986 CIN No: L24299MH1977PLC019982 W: www.glenmarkpharma.com
Registered office: B/2, Mahalaxmi Chambers, 22 Bhulabhai Desai Road, Mumbai 400 026 E: complianceofficer@glenmarkpharma.com